The NHS doesn’t decide this arbitrarily. It’s based on NICE guidance, clinical trial evidence, safety data, and cost-effectiveness rules.

Here’s why this happens:

1. The 2-year nivolumab limit is evidence-based

For advanced melanoma, most trials of nivolumab (and pembrolizumab) were designed with:

👉 Treatment for up to 2 years

👉 Or until progression

👉 Or until unacceptable toxicity

What NICE looks at is:

Does continuing beyond this point improve survival? Does it reduce relapse? Does it justify the risk and cost?

So far, the data shows:

✅ Many patients maintain long-term control after stopping

❌ No strong evidence that going beyond 2 years improves outcomes

❌ Side effects accumulate over time

So they approve funding only within the window where benefit is proven.

2. If you can’t tolerate nivolumab, continuing is unsafe

This is critical.

If someone develops significant immune toxicity (bowel, liver, lungs, endocrine, etc.), then:

Restarting the same drug can be dangerous and the side effects often return faster and worse. Some reactions can become life-threatening

So the NHS won’t fund something that:

❌ Has a high risk of serious harm

❌ Has no evidence of additional benefit

❌ Could permanently damage organs

This is not about money — it’s about safety and evidence.

3. NICE only funds treatments that meet strict rules

For a treatment to be funded, it must:

✔ Improve survival or quality of life

✔ Be supported by trial data

✔ Be safe enough for real-world use

✔ Be cost-effective

If someone cannot tolerate nivolumab, and there is no trial evidence showing benefit of continuing or switching within that specific situation, NICE will not approve it.

Doctors’ hands are often tied here.

4. This feels cruel — but the logic is clinical, not personal

This is not a judgement about whether someone deserves more treatment. It is not about giving up on someone and it’s not because they are “too complex”.

It’s because the NHS must follow:

Evidence Safety National rules even when those rules feel brutally unfair.

5. BUT — this does NOT mean “no more options”

If someone cannot tolerate nivolumab, doctors can still consider:

Possible alternatives (depending on case):

• Targeted therapy (if BRAF+)
• Surgery for isolated disease
• Radiotherapy Clinical trials
• Rechallenge under special circumstances
• Compassionate use requests
• Different immunotherapy sequencing

These require individual MDT discussion.

It’s massively important that all the side effects that the treatment cause a reported to your team so that immediate decisions can be made about how to curb the side effects.

Keeping a positive state of mind through all this is critical and is the hardest part of any of the treatment cycles. It’s at this stage that you really start to question your body’s ability to withstand the constant barrage of the cancer itself or indeed the treatment that is required to try and give you some sort of longer life with a decent quality of life included.

My message to you is never to give up – life is too short and I’m sure many of us all have things that we would love to be able to do at some point in the future.

The NHS doesn’t decide this arbitrarily. It’s based on NICE guidance, clinical trial evidence, safety data, and cost-effectiveness rules.

Here’s why this happens:

1. The 2-year nivolumab limit is evidence-based

For advanced melanoma, most trials of nivolumab (and pembrolizumab) were designed with:

👉 Treatment for up to 2 years

👉 Or until progression

👉 Or until unacceptable toxicity

What NICE looks at is:

Does continuing beyond this point improve survival? Does it reduce relapse? Does it justify the risk and cost?

So far, the data shows:

✅ Many patients maintain long-term control after stopping

❌ No strong evidence that going beyond 2 years improves outcomes

❌ Side effects accumulate over time

So they approve funding only within the window where benefit is proven.

2. If you can’t tolerate nivolumab, continuing is unsafe

This is critical.

If someone develops significant immune toxicity (bowel, liver, lungs, endocrine, etc.), then:

Restarting the same drug can be dangerous and the side effects often return faster and worse. Some reactions can become life-threatening

So the NHS won’t fund something that:

❌ Has a high risk of serious harm

❌ Has no evidence of additional benefit

❌ Could permanently damage organs

This is not about money — it’s about safety and evidence.

3. NICE only funds treatments that meet strict rules

For a treatment to be funded, it must:

✔ Improve survival or quality of life

✔ Be supported by trial data

✔ Be safe enough for real-world use

✔ Be cost-effective

If someone cannot tolerate nivolumab, and there is no trial evidence showing benefit of continuing or switching within that specific situation, NICE will not approve it.

Doctors’ hands are often tied here.

4. This feels cruel — but the logic is clinical, not personal

This is not a judgement about whether someone deserves more treatment. It is not about giving up on someone and it’s not because they are “too complex”.

It’s because the NHS must follow:

Evidence Safety National rules even when those rules feel brutally unfair.

5. BUT — this does NOT mean “no more options”

If someone cannot tolerate nivolumab, doctors can still consider:

Possible alternatives (depending on case):

• Targeted therapy (if BRAF+)
• Surgery for isolated disease
• Radiotherapy Clinical trials
• Rechallenge under special circumstances
• Compassionate use requests
• Different immunotherapy sequencing

These require individual MDT discussion.

It’s massively important that all the side effects that the treatment cause a reported to your team so that immediate decisions can be made about how to curb the side effects.

Keeping a positive state of mind through all this is critical and is the hardest part of any of the treatment cycles. It’s at this stage that you really start to question your body’s ability to withstand the constant barrage of the cancer itself or indeed the treatment that is required to try and give you some sort of longer life with a decent quality of life included.

My message to you is never to give up – life is too short and I’m sure many of us all have things that we would love to be able to do at some point in the future.